Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 40Neoplasms, Plasma Cell 5Neoplasms 5Recurrence 4Renal Insufficiency 3Paraproteinemias 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Blood Protein Disorders 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Plasma Cell 1Immunoproliferative Disorders 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Cryoglobulinemia, Familial Mixed 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Recurrence × isatuximab × Clear all
NCT05911321 2026-05-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
6 enrolled 5 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT06832865 2026-03-12

ELISA in Relapsed/Refractory MM

Massachusetts General Hospital

Phase 2 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

Massachusetts General Hospital

Phase 2 Recruiting
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02332850 2025-05-01

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1 Active not recruiting
83 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡